cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
-
Contact Email
-
Phone
-
Journal Mail Official
-
Editorial Address
-
Location
Kota malang,
Jawa timur
INDONESIA
MNJ (Malang Neurology Journal)
Published by Universitas Brawijaya
ISSN : 24076724     EISSN : 24425001     DOI : -
Core Subject : Science,
Neuroscience
Malang Neurology Journal is a peer-reviewed and open access journal that focuses on promoting neurological sciences generated from basic neurosciences and clinical neurology. This journal publishes original articles, reviews, and also interesting case reports. Brief communications containing short features of medicine, latest developments in diagnostic procedures of neurology disease, treatment, or other health issues related to neurology that is important also acceptable. Letters and commentaries of our published articles are welcome.
Arjuna Subject : -
Articles 278 Documents
 24   25   26   27   28 
A RETROSPECTIVE COMPARATIVE STUDY OF THE EFFECTS AND SIDE EFFECTS OF LEVETIRACETAM AGAINST SODIUM VALPROATE IN PATIENTS DIAGNOSED WITH GENERALIZED EPILEPSY Fattahzadeh, Ghasem; Amani, Firouz; Mohammadi, Nayyereh
MNJ (Malang Neurology Journal) Vol. 11 No. 1 (2025): January
Publisher : PERDOSSI (Perhimpunan Dokter Spesialis Saraf Indonesia Cabang Malang) - Indonesian Neurological Association Branch of Malang cooperated with Neurology Residency Program, Faculty of Medicine Brawijaya University, Malang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.mnj.2025.011.01.23

Abstract

Background: Nearly one in every 28 people will receive a diagnosis of epilepsy at some point in their lives, but nearly half of those individuals do not receive treatment using the medications available today. It's still difficult to choose the right antiepileptic medication because it needs to be safe, effective, and bearable. For children older than one year, levetiracetam, a recently approved experimental antiepileptic, can be used as an adjuvant treatment for seizures. Objective: The purpose of this study was to assess levetiracetam's safety and effectiveness as an adjuvant treatment for epilepsy in Iranian children and adults. Method: Methods: Two groups of 100 patients each receiving treatment with sodium valproate and levetiracetam were included in this cross-sectional and analytical study, which involved 200 patients with generalized epilepsy who were referred to the neurology clinics of Alavi Hospital in Ardabil between 2014 and 2019. By looking through the patient files, the necessary data was gathered, such as demographics, drug side effects, degree of satisfaction with the course of therapy, and the drug's effectiveness in controlling seizures. Based on the study's goals, pertinent data was assessed by entering it into the SPSS version 17 program. Results: Findings: There was no significant difference in the average age or gender distribution between the two groups receiving sodium valproate and levetiracetam treatment (P=0.203 and P=0.384, respectively). Headache and nausea were the most frequent adverse effects of sodium valproate and levetiracetam, respectively. While 71% of patients treated with sodium valproate had good seizure control (P<0.001), 23% and 55% of patients treated with Lobel medication had moderate and good seizure control, respectively. Additionally, 68% of the Sodium Valproate group reported good satisfaction with the treatment, compared to 50% and 24% of the Lobel receiving group (P<0.001). While 20% of patients treated with sodium valproate experienced more than three pharmacological issues, the majority of patients (82%) treated with Lobel experienced no drug difficulties at all. Conclusion: Despite its poor performance in this area when compared to sodium valproate, the Lobel medication generally has positive effects on seizure control and patient satisfaction. On the other hand, patients treated with Lobel have experienced significantly fewer drug side effects than those treated with sodium valproate.
EFFECTS OF MSC-DERIVED SECRETOME TOWARDS PLASMA-TOTAL CHOLESTEROL LEVELS ON ROTENONE-INDUCED PARKINSON’S DISEASE RAT MODELS Putria, Fani Mustika; Sasmita, Poppy Kristina; Sidharta, Veronika Maria; Ardianto, Christian; Barus, Jimmy
MNJ (Malang Neurology Journal) Vol. 11 No. 2 (2025): July
Publisher : PERDOSSI (Perhimpunan Dokter Spesialis Saraf Indonesia Cabang Malang) - Indonesian Neurological Association Branch of Malang cooperated with Neurology Residency Program, Faculty of Medicine Brawijaya University, Malang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.mnj.2025.011.02.01

Abstract

Background: Parkinson's disease (PD), a chronic progressive neurodegenerative disease, threatens much of the world's increasingly aging population and has no promise for disease-modifying drugs, only symptomatic treatment. One potential biomarker correlates PD to the disruption of cholesterol metabolizing processes that results in formation of cytotoxic bile acids (BA) which induces mitochondrial dysfunction that leads to the decrease of dopaminergic neurons in various PD models. Objective: This study aims to determine the effect of rotenone-induction as well as MSC-Secretome administration on plasma-total cholesterol levels in rat models.. Methods: This was an experimental research using 30 male Sprague Dawley rats divided into sham control, rotenone (+) secretome (-) and rotenone (+) secretome (+). Blood was withdrawn on day 0 and day 8 and analyzed under colorimetry and spectrophotometry for its plasma-total cholesterol concentration. Results: The Tukey Post-Hoc Test showed that there was no significant difference between the sham control and rotenone (+) secretome (-)  (p = 0.073), plasma-total cholesterol level is lower in rotenone (+) secretome (-) than in the sham control. Furthermore, we were unable to prove for a significant difference between the rotenone (+) secretome (-) and rotenone (+) secretome (+) group (p= 0.234), even though in average the plasma-total cholesterol level is lower in the rotenone (+) secretome (+)  group. Conclusion: Induction of rotenone followed by an intervention of MSC-Secretome has no effect on the change in plasma-total cholesterol levels on rat models.
EFFICACY OF ELECTRICAL STIMULATION (ES) ON DYSPHAGIA IN POST-STROKE PATIENTS: A SYSTEMATIC REVIEW Modesty, Kyra; Sitepu, Brigitta Ellycia; Budianto, Pepi; Probandari, Ari; Tandiyo, Desy Kurniawati
MNJ (Malang Neurology Journal) Vol. 11 No. 2 (2025): July
Publisher : PERDOSSI (Perhimpunan Dokter Spesialis Saraf Indonesia Cabang Malang) - Indonesian Neurological Association Branch of Malang cooperated with Neurology Residency Program, Faculty of Medicine Brawijaya University, Malang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.mnj.2025.011.02.08

Abstract

Background: Stroke is a disease that can occur in both developed and developing countries and is the second leading cause of death in the world. Stroke can cause various complications such as dysphagia. This study examines the efficacy of electrical stimulation (ES) as a treatment for dysphagia in post- stroke patients with various measurements of the severity of dysphagia. Objective: This study aims to review the efficacy of electrical stimulation on dysphagia in post-stroke patients. Methods: This study uses a systematic review method by following the guidelines from PRISMA. Articles are arranged based on keywords that have been determined in PICO, namely electrical stimulation, dysphagia, and stroke. Articles included in the inclusion criteria are RCTs, in English, and published between January 2013 and January 2023. Results: Eighteen studies that met the inclusion criteria were critically reviewed by the two authors. There were ten types of outcomes included in this systematic review and six of them had significant results for reducing the severity of dysphagia. Conclusion: ES can be given as the main therapy for post-stroke dysphagia patients. The six types of outcomes used to measure the degree of dysphagia, namely FOIS, PAS, FDS, PTT, OTT, and MASA, showed high significance associated with a reduction in the degree of dysphagia thereby reducing the risk of aspiration pneumonia by using this ES therapy.
THE RELATIONSHIP OF THE CHARACTERISTICS OF ANTI-EPILEPSY DRUGS WITH THE C OGNITIVE FUNCTION OF EPILEPSY PATIENTS Handayani, Sri; Partan, Radiyati Umi; Hafy, Zen; Octaviana, Fitri; Harun, Yusril; Bahar, Erial; Lestari, Nova
MNJ (Malang Neurology Journal) Vol. 11 No. 2 (2025): July
Publisher : PERDOSSI (Perhimpunan Dokter Spesialis Saraf Indonesia Cabang Malang) - Indonesian Neurological Association Branch of Malang cooperated with Neurology Residency Program, Faculty of Medicine Brawijaya University, Malang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.mnj.2025.011.02.02

Abstract

Background: One of the side effects of the use of antiepileptic drugs (AEDs) is cognitive disorder. Several studies show a relationship between the type of AEDs and cognitive disturbance in people with epilepsy. Dose-dependent side effects of AEDs have also been reported in prior research. However, there are results from different studies on different populations. Objective: This research aims to evaluate the relationship between AEDs characteristics and the cognitive function of epilepsy patients. Methods: This cross-sectional study was conducted in the Neurology Department of Dr. Mohammad Hoesin General Hospital Palembang, from 1 November 2021 to 31 March 2022. Researchers used the MoCA-Ina questionnaire to collect medical record data and conduct interviews. Results: In this research, the number of research subjects obtained was 70 people with epilepsy. Characteristics of sociodemographic sufferer Epilepsy in this study was mostly (44.3%) aged 26 – 45 years with type sex most were women (71.4%), and the majority subjects (52.9%) had level high school education. Characteristics of antiepileptic drugs consumed by people living with epilepsy: most of them, i.e., amounting to 57.1%, have consumed antiepileptic drugs for > 12 months. Most of the research subjects (64.3%) had function-impaired cognitive range MoCA-Ina scores of 8 – 30. The function most cognitively disturbed, namely in the memory domain, cancels that am, counting to 82.9%. Education level is the only variable from characteristics of sociodemographic and clinical features connected significantly to cognitive function in general (p-value 0.013). The number, duration, and type of antiepileptic drugs do not determine a significant relationship with cognitive function in general. Conclusion: There is a significant relationship between valproic acid and the number of AEDs with the naming domain, as well as between valproic acid and the duration of AEDs with the abstraction domain.
SLEEP DISORDERS AND DIVING-ASSOCIATED DECOMPRESSION SICKNESS Harahap, Herpan Syafii; Indrayana, Yanna; Afif, Zamroni; Landapa, Raditya Rachman; Ismiana, Baiq Holisatul; Gea, Endah Irnanda Ulfa; Wiracakra, I Gusti Lanang Krisna
MNJ (Malang Neurology Journal) Vol. 11 No. 2 (2025): July
Publisher : PERDOSSI (Perhimpunan Dokter Spesialis Saraf Indonesia Cabang Malang) - Indonesian Neurological Association Branch of Malang cooperated with Neurology Residency Program, Faculty of Medicine Brawijaya University, Malang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.mnj.2025.011.02.09

Abstract

Decompression sickness is considered as an important complication of deep diving. Since the trend of diving activities is increasing throughout the world and is dominated by novice divers, the incidence of decompression sickness should be high. Severe form of decompression sickness can cause damage to the central nervous system with varying manifestations of mild to severe neurological deficits. Recent studies show that sleep disorders need to be considered as an important consequence of decompression sickness. However, the pathophysiology of decompression sickness-associated sleep disorders is currently not well understood. Since sleep disorders are associated with dysfunction of anatomical structures and the neurotransmitter systems in the brain that regulate the sleep-wakefulness cycle, decompression sickness-associated sleep disorders can be postulated to be related to dysfunction of these two regulators of sleep-wakefulness cycle. Sleep disorders found in patients with decompression sickness are more likely to occur in type 2 decompression sickness and may be found in the form of insomnia, hypersomnia, circadian rhythm disorders, obstructive sleep apnea, and narcolepsy. This review aims to discuss the pathophysiology of sleep disorders and decompression sickness as well as possible mechanisms underlying sleep disorders in decompression sickness through theoretical approaches and the results of available studies. In conclusion, decompression sickness-related sleep disorders are thought to involve two pathological conditions in the brain, namely structural lesions and dysfunction of the neurotransmitter system in the brain.
THE THE POTENTIAL ROLE OF NRF2 AS A TARGET SITE FOR THERAPEUTIC INTERVENTIONS IN ALZHEIMER'S DISEASE Rivarti, Arina Windri; Harahap, Herpan Syafii; Saputri, Legis Ocktaviana; Suryani, Dini; Rianawati, Sri Budhi
MNJ (Malang Neurology Journal) Vol. 11 No. 2 (2025): July
Publisher : PERDOSSI (Perhimpunan Dokter Spesialis Saraf Indonesia Cabang Malang) - Indonesian Neurological Association Branch of Malang cooperated with Neurology Residency Program, Faculty of Medicine Brawijaya University, Malang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.mnj.2025.011.02.10

Abstract

Alzheimer's Disease (AD) is the most common form of dementia, characterized by progressive neurodegeneration leading to cognitive decline and memory impairment, affecting various cognitive functions. AD pathology involves the accumulation of neurotoxic substances such as amyloid beta (Aβ) and tau proteins, mitochondrial dysfunction, oxidative stress, and chronic neuroinflammation, resulting in synaptic loss and neuronal apoptosis. The transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) has emerged as a pivotal regulator of cellular defense mechanisms, including antioxidant response, autophagy, and inflammation. NRF2 not only inhibits Aβ synthesis and enhances tau protein clearance via autophagy but also reduces neuroinflammation by modulating microglial activation and cytokine production. Additionally, NRF2 activation preserves mitochondrial function by attenuating reactive oxygen species (ROS) production and sustaining mitochondrial biogenesis. Recent studies highlight the therapeutic potential of NRF2 activators, such as sulforaphane and echinacoside, in preclinical AD models, demonstrating reductions in Aβ and tau pathologies and improved cognitive outcomes. These findings underscore the multifaceted role of NRF2 in mitigating AD progression and its promise as a target for developing novel therapeutic interventions. By integrating NRF2-based strategies, future treatments may offer more effective approaches to combat the complex pathophysiology of AD.
SIDE EFFECTS OF TEMOZOLOMIDE CHEMOTHERAPY IN GLIOMA AND MANAGEMENT Sukmala Ratih, Dwita; Rahmawati, Dessika
MNJ (Malang Neurology Journal) Vol. 11 No. 2 (2025): July
Publisher : PERDOSSI (Perhimpunan Dokter Spesialis Saraf Indonesia Cabang Malang) - Indonesian Neurological Association Branch of Malang cooperated with Neurology Residency Program, Faculty of Medicine Brawijaya University, Malang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.mnj.2025.011.02.11

Abstract

Glioma is the most common type of primary brain tumor and is characterized by aggressive growth, angiogenesis, and invasion. Current therapies for malignant glioma have limited efficacy, necessitating new treatment strategies.1 Every year, approximately 100,000 people worldwide are diagnosed with glioma. These tumors are categorized based on tumor histology and molecular alterations. Survival rates depend on tumor subtype, age, and gender.4 Glioblastoma is a specific type of glioma and is the most aggressive and malignant form. It is often linked to unfavorable outcomes and has few available treatment choices.2 Temozolomide is a drug used in the treatment of glioma, which is the most common primary malignant tumor of the Central Nervous System (CNS). It is a chemotherapy drug that is often used in combination with radiation therapy to treat gliomas. It works by damaging the DNA in cancer cells, which prevents them from dividing and growing. This agent may help slow or stop tumor growth. TMZ is often used in combination. Close monitoring of patients receiving bevacizumab or temozolomide is required to manage potential side effects resulting from the use of these regimens.3
THE NEUROPROTECTIVE EFFECT OF HONEY’S POLYPHENOL FOR THE POTENTIAL TREATMENT OF NEURODEGENERATIVE DISEASES: A SYSTEMATIC REVIEW Soenarti, Sri; Nanda Utama, Gede; Utomo, Vidi Prasetyo
MNJ (Malang Neurology Journal) Vol. 11 No. 2 (2025): July
Publisher : PERDOSSI (Perhimpunan Dokter Spesialis Saraf Indonesia Cabang Malang) - Indonesian Neurological Association Branch of Malang cooperated with Neurology Residency Program, Faculty of Medicine Brawijaya University, Malang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.mnj.2025.011.02.12

Abstract

Background: Neurodegenerative disorders, such as Alzheimer's and Parkinson's, are distinguished by the progressive deterioration of the central nervous system's structure and functionality. Their pathophysiology is significantly influenced by neuroinflammation and oxidative stress. Natural honey, high in polyphenols and flavonoids, may be useful in the treatment of various ailments. Methods: This systematic review follows the PRISMA guidelines, covering literature searches conducted from June 1 to July 20, 2024. Included studies were published in the last decade and focused on the effects of honey on neurodegenerative diseases. Results: The review included six studies, comprising four in vivo studies and two in vitro studies. The in vivo studies used rodents and nematodes as subjects. Honey demonstrated significant neuroprotective effects in Parkinson's disease models, including improved motor coordination and reduced neuronal damage. In Alzheimer's disease models, honey reduced amyloid-β aggregation and enhanced antioxidant defences. Discussion: The studies indicate that honey has anti-inflammatory and antioxidant benefits, helping to reduce oxidative stress and prevent neuronal damage. The polyphenols and flavonoids in honey also increased the concentration and activity of antioxidant enzymes such as glutathione (GSH) and superoxide dismutase (SOD). Additionally, honey can boost the expression of Brain-Derived Neurotrophic Factor (BDNF), which is crucial for synaptic plasticity and cognitive performance. Conclusion: Honey, particularly its polyphenol and flavonoid components, shows potential as a neuroprotective agent for neurodegenerative diseases. However, further research, especially clinical trials in humans, is needed to confirm these findings and explore the therapeutic potential of honey more comprehensively.
PREDICTION OF MADECASSOSIDE (CENTELLA ASIATIACA) AFFINITY AS ANTIPARKINSON DRUG ON DOPAMINE RECEPTOR D1: MOLECULAR DOCKING ANALYSIS Shinta Kusumawati; Khotimah, Husnul; Endharti, Agustina Tri; Balafif, Farhad; Zakiyah, Rima
MNJ (Malang Neurology Journal) Vol. 11 No. 2 (2025): July
Publisher : PERDOSSI (Perhimpunan Dokter Spesialis Saraf Indonesia Cabang Malang) - Indonesian Neurological Association Branch of Malang cooperated with Neurology Residency Program, Faculty of Medicine Brawijaya University, Malang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.mnj.2025.011.02.03

Abstract

Background: Parkinson's disease results from the gradual degeneration of dopamine neurons in the brain's substantia nigra pars compacta. The Dopamin receptor D1 (DRD1), which controls nerve growth and behavior, is the most prevalent dopamine receptor in the human nervous system. Objective: To determine the affinity of madecassoside on dopamine D1 receptors as a potential for anti-Parkinson's medications. Methods: The RSCB PDB database provided the chosen target protein's three-dimensional structure. namely DRD1. The PubChem database provided the 3D structure of the Madecassoside sample (CID: 45356919) and the PDB ligand control Rotigotine (CID: 59227). Autodock Vina, which was integrated with Pyrx v.1, was used for docking. Results: The madecassoside has a lower binding energy than the PDB control in the form of Rotigotine. The docking results showed that  madecassoside compounds formed more hydrogen bonds than Rotigotine. It was predicted that madecassoside and the dopamin receptor 1 receptor would create a stability complex. Conclusion: Madecassoside was predicted create a stability complex with DRD1.
COGNITIVE FUNCTION PROFILE IN OBSTRUCTIVE SLEEP APNEA PATIENTS: WHICH IS MORE LIKELY TO DEVELOP? Wardani, Rachmawati; Afif, Zamroni
MNJ (Malang Neurology Journal) Vol. 11 No. 2 (2025): July
Publisher : PERDOSSI (Perhimpunan Dokter Spesialis Saraf Indonesia Cabang Malang) - Indonesian Neurological Association Branch of Malang cooperated with Neurology Residency Program, Faculty of Medicine Brawijaya University, Malang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.mnj.2025.011.02.04

Abstract

Background: Obstructive sleep apnea (OSA) is a condition that arises from repeated episodes of upper airway collapse and obstruction during sleep that are associated with waking events with or without oxygen desaturation. OSA can cause a decrease in cognitive function. There are several neurocognitive areas of the brain that OSA and sleep deprivation can affect differently. Objective: The aim of this study is to determine the profile of cognitive disorders in OSA patients at dr. Saiful Anwar General Hospital from 2017 to 2022. Methods: This is an observational descriptive study of the results of Polysomnography and Mini-Mental State Examination (MMSE) of patients with OSA at dr. Saiful Anwar General Hospital during the period January 2017 - April 2022. Results: Results: Among the 100 subjects of the study, there were 63 men (63%) and 37 women (37%). The age distribution was as follows: 20 individuals were under 25 years old (20%), 36 people were between 25 and 45 years old (36%), 24 people were between 46 and 60 years old (24%), and 20 people were over 60 years old (20%). 12 individuals (12%) had an elementary education, 17 individuals (17%) had a junior high school education, 36 individuals (36%) had a senior high school education, and 34 individuals (34%) had an undergraduate education, according to the most recent education subject. According to the study participants' cognitive function profiles, 93 individuals (93%) had normal cognitive function, 5 individuals (5%) had mild cognitive function impairment, 2 individuals (2%) had moderate cognitive impairment, and none of the study participants had severe cognitive impairment. Conclusion: Most cognitive function profiles were normal, and the majority of OSA patients at dr. Saiful Anwar General Hospital are men. Few people acquired mild to moderate cognitive deficits and no severe cognitive impairment was seen.

Page 27 of 28 | Total Record : 278

 24   25   26   27   28 

Filter by Year

2015 2025


Reset
Filter By Issues
All Issue Vol. 11 No. 2 (2025): July Vol. 11 No. 1 (2025): January Vol. 10 No. 2 (2024): July Vol. 10 No. 1 (2024): January Vol. 9 No. 2 (2023): July Vol. 9 No. 1 (2023): January Vol. 8 No. 2 (2022): July Vol. 8 No. 1 (2022): January Vol. 7 No. 2 (2021): July Vol. 7 No. 1 (2021): January Vol. 6 No. 2 (2020): July Vol 6, No 1 (2020): January Vol 5, No 2 (2019): July Vol 5, No 1 (2019): January Vol 5, No 1 (2019): January Vol 4, No 2 (2018): July Vol 4, No 1 (2018): January Vol 4, No 1 (2018): January Vol 3, No 2 (2017): July Vol 3, No 1 (2017): January Vol 2, No 2 (2016): July Vol 2, No 2 (2016): July Vol 2, No 1 (2016): January Vol 2, No 1 (2016): January Vol 1, No 2 (2015): July Vol 1, No 1 (2015): January More Issue